Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
DCPH was delisted on the 10th of June, 2024.
80 hedge funds and large institutions have $522M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 26 reducing their positions, and 9 closing their positions.
22% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 9
14% more capital invested
Capital invested by funds: $460M → $522M (+$62.1M)
3% more funds holding
Funds holding: 78 → 80 (+2)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 26
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$30.8M |
| 2 |
KCM
Kingdon Capital Management
New York
|
+$4.84M |
| 3 |
EP
Eversept Partners
New York
|
+$4.73M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$4.54M |
| 5 |
Alkeon Capital Management
New York
|
+$4.06M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$6.97M |
| 2 |
EMFAT
Emerald Mutual Fund Advisers Trust
Leola,
Pennsylvania
|
-$6.52M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.3M |
| 4 |
EA
Emerald Advisers
Leola,
Pennsylvania
|
-$5.75M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.51M |
DCPH Hedge Fund Activity: Q1 2019 in Review
80 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q1 2019, worth a combined $522M — up 14% from $460M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DCPH positions and 9 closed out — a net gain of 2 holders — while 25 added to existing stakes and 26 trimmed.
The largest buyer was OrbiMed, adding an estimated $30.8M. The largest seller was Norges Bank, exiting entirely with an estimated $6.97M sold.
- 80 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q1 2019, up from 78 in Q4 2018.
- Funds reported $522M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q1 2019, up 14% quarter-over-quarter.
- 11 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q1 2019 and 9 closed out, a net change of +2 holders.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q1 2019 was OrbiMed, an estimated $30.8M added.
- The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q1 2019 was Norges Bank, an estimated $6.97M sold.
Based on aggregated 13F filings for Q1 2019.